<DOC>
	<DOCNO>NCT01813773</DOCNO>
	<brief_summary>To assess safety intravitreal aflibercept injection treatment proliferative diabetic retinopathy ( PDR ) evaluate incidence severity adverse event .</brief_summary>
	<brief_title>Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy , The A.C.T Study</brief_title>
	<detailed_description>- Single center , open label pilot study use 2.0mg intravitreal aflibercept injection . ( IAI ) - 20 subject active PDR randomize 2 group , i.e . group A B . - Subjects arm followed-up every 4 week week 52 . - The primary endpoint study week 52 .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Subjects enrol follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age 18 year old Retinal neovascularization secondary diabetic retinopathy Best correct visual acuity study eye well 20/320 use ETDRS chart In event either eye potential subject meet enrollment criterion , bad sight eye enrol study . Only one eye enrol study . Pregnant breastfeed woman Sexually active men* woman childbearing potential** unwilling practice adequate contraception study least 30 day last administration study drug woman least 90 day last administration men ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) *Contraception require men document vasectomy . ** Pregnancy test contraception require woman document hysterectomy . HbA1C &gt; 10 within approximately 90 day Screening visit Participation study investigational drug device within 30 day prior potential enrollment study Prior treatment systemic antiVEGF agent Presence substantial ocular disease ( diabetic retinopathy ) may compromise vision study eye /or confound interpretation data ; e.g . substantial cataract , advance glaucoma , optic neuritis , optic neuropathy atrophy , mark macular atrophy , ocular vascular occlusion , history retinal detachment , uveitis , viral form chorioretinitis , etc . Prior treatment antiVEGF therapy study eye within 90 day baseline Prior treatment PRP within 60 day Prior treatment IAI . Prior treatment triamcinolone study eye within 180 day baseline . Prior treatment dexamethasone study eye within 30 day prior baseline . Intraocular surgery ( include cataract surgery ) study eye within 60 day precede baseline History vitrectomy surgery study eye . Active intraocular inflammation ( grade trace ) study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Uncontrolled glaucoma study eye ( defined IOP â‰¥ 25 mmHg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 180 day study enrollment . History allergy fluorescein , topical antibiotic , povidone iodine ( Betadine ) aflibercept . Presence vitreous hemorrhage completely obstruct view optic nerve ( amount vitreous hemorrhage also gate 20/320 criterion ) Presence TRD study eye . Presence preretinal fibrosis ( include epiretinal membrane ) Unwilling discontinue sperm bank donation period time IAI treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>